Bluejay Diagnostics Secures $8.5M in Deeply Discounted Private Placement, Potential $23.6M Total
BJDX has more than doubled off its 52-week low of $1.623 on elevated volume (59× avg).
Summary
Bluejay Diagnostics announced a private placement to raise $8.5 million upfront, with potential for an additional $15.1 million from warrant exercises, totaling up to $23.6 million. The shares and warrants are priced at $2.325 and $2.075 respectively, a deep discount to the current $4.6277 market price. This follows the May 7th 10-Q, which reported only $3.7 million in cash and a critical going concern warning. While the $8.5 million extends the cash runway into Q1 2027 and funds FDA efforts, the offering is highly dilutive, with the total potential raise significantly exceeding the company's $2.24 million market capitalization.
At the time of this announcement, BJDX was trading at $4.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.62 to $16.68. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.